Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial☆ | Zendy

José I. Aramendi | Zendy; Carlos-Alfonso Mestres | Zendy; Juan Martínez-León | Zendy; Vicente Campos | Zendy; Genı́s Muñoz | Zendy; Carlos A. Navas | Zendy

Open Access

Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial☆

Author(s) -

José I. Aramendi,

Carlos-Alfonso Mestres,

Juan Martínez-León,

Vicente Campos,

Genı́s Muñoz,

Carlos A. Navas

Publication year - 2005

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2004.12.064

Subject(s) - medicine , acenocoumarol , warfarin , surgery , randomized controlled trial , clinical endpoint , atrial fibrillation , prospective cohort study , anticoagulant , anesthesia

Antiplatelet agents are used for prevention of thromboembolism in surgical patients and in patients with chronic atrial fibrillation. Up to date, however, results of randomized studies comparing antiplatelet agents and oral anticoagulation have not been reported. The aim of this study was to compare the efficacy and safety of triflusal (an antiplatelet agent) versus acenocoumarol for primary prevention of thromboembolism in the early postoperative period after implantation of a bioprosthesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research